Abstract
Non-invasive quantification of myocardial β-receptors could become an independent prognostic marker for chronic heart failure and cardiovascular disorders. The aim of this study was to formulate a novel radiopharmaceutical for the detection of myocardial infarction at early stages in susceptible patients, which requires the development of high myocardium affinity radiopharmaceuticals able to establish an accurate in vivo quantification of cardiac β1-adrenoceptors. This was attained by the direct complexation of nebivolol as a cardioselective agent with technetium-99m as one of the most useful radionuclides in diagnostic nuclear medicine. Factors affecting the radiochemical yield such as nebivolol amount, stannous chloride amount, reaction time and pH of the reaction mixture were optimized. The results showed that the radiochemical yield was 95 ± 2.87 % and the radiolabeled compound was separated by high performance liquid chromatography. In vitro studies showed that the formed complex was stable for up to 24 h. In vivo uptake of 99mTc-nebivolol in the heart was 4.55 ± 0.23 % ID/g organ at 0.5 h post injection, whereas the clearance from Albino mice appeared to proceed via the hepatobiliary and renal clearance pathways. Predosing mice with cold nebivolol reduced the heart uptake to 1.1 ± 0.02 % and further confirmed the high specificity and selectivity of this radiotracer for the assessment of the myocardial β1-adrenoceptors.
Similar content being viewed by others
References
Indian Pharmacopoeia (2010) vol 3. New Delhi, p 1753
Pawels PJ, Gommery W, Van Lommen G, Janssen PAJ, Leysen JE (1989) Mol Pharmacol 34:843
Pawels PJ, Gommery W, Van Gompel P, Leysen JE (1991) Biochem Pharmacol 42:1683
The NIH Website. http://dailymed.nlm.nih.gov/dailymed/. Accessed 10 2008
Bundkirchena A, Nguyena Q, Brixiusa K, Bölck B, Mehlhorn U, Schwingera RHG (2003) Eur J Pharmacol 476:97
Brixiusa K, Bundkirchena A, Bölck B, Mehlhorn U, Schwinger RHG (2001) Br J Pharmacol 133:1330
Maack C, Tyroller S, Schnabel P, Cremers B, Dabew E, SuÈdkamp M, BoÈhm M (2001) Br J Pharmacol 132:1817
Mangrella M, Rossi F, Fici F (1998) Pharmacol Res 38:419
Münzel T, Gori T (2009) J Am Coll Cardiol 54:16
Schnabel P, Maack C, Mies F, Tyroller S, Scheer A, Böhm M (2000) J Cardiovasc Pharmacol 36:466
Smith C, Teitler M (1999) Cardiovasc Drugs Ther 13:123
Cheng YC, Prussoff WH (1973) Biochem Pharmacol 22:3099
Sarsero D, Molenaar P, Kaumann AJ, Freestone NS (1999) Br J Pharmacol 128:1445
Brodde OE, Michel MC (1999) Pharmacol Rev 51:651
Molenaar P, Parsonage WA (2005) Trends Pharmacol Sci 26:368
Brodde OE, Bruck H, Leineweber K (2006) J Pharmacol Sci 100:323
Castellano M, Böhm M (1997) Hypertension 29:715
Yamada S, Ohkura T, Uchida S, Inabe K, Iwatani Y, Kimura R, Hoshino T, Kaburagi T (1996) Life Sci 58:1737
Khamssi M, Brodde OEJ (1996) Cardiovasc Pharmacol 16(Suppl 5):S133
Brodde OE, Zerkowski HR, Doetsch N, Motomura S, Khamssi M, Michel MC (1989) J Am Coll Cardiol 14:323
Anthonio RL, Brodde OE, van Veldhuisen DJ, Scholtens E, Crijns HJ, van Gilst WH (2000) Int J Cardiol 72:137
Schäfers M, Dutka D, Rhodes CG, Lammertsma AA, Hermansen F, Schober O, Camici PG (1998) Circ Res 82:57
Dubois EA, van den Bos JC, Doornbos T, van Doremalen PA, Somsen GA, Vekemans JA, Janssen AG, Batink HD, Boer GJ, Pfaffendorf M, van Royen EA, van Zwieten PA (1996) J Med Chem 39:3256
van den Bos C, van Doremalen PA, Dubois E, Somsen GA, Vekemans JA, Janssen AG, Boer GJ, Pfaffendorf M, van Royen EA, van Zwieten PA (1997) Nucl Med Biol 24:1
Dubois EA, Somsen GA, van den Bos JC, Janssen AG, Batink HD, Boer GJ, van Royen EA, van Zwieten PA (1997) Nucl Med Biol 24:9
Elsigna PH, van Waarde A, Jaeggi KA, Schreiber G, Heldoorn M, Vaalburg W (1997) J Med Chem 40:3829
de Jong RM, Willemsen ATM, Slart RHJA, Blanksma PK, van Waarde A (2005) Eur J Cardiovasc Nurs 4:99
Delforge J, Syrota A, Lancon JP, Nakajima K, Loch C, Janier M, Vallois JM, Cayla J, Crouzel C (1991) J Nucl Med 32:739
Soloviev DV, Matarrese M, Moresco RM, Todde S, Buonasera TA, Sudati F, Simonelli P, Magni F, Colombo D, Carpinelli A, Kienle MG, Fazio F (2001) Neurochem Int 38:169
Valette H, Dolle F, Guenther I, Demphel S, Rasetti C, Hinnen F, Fuseau C, Crouzel C (1999) Nucl Med Biol 26:105
van Waarde A, Meeder JG, Blanksma PK, Brodde OE, Visser GM, Elsinga PH, Paans AMJ, Vaalburg W, Lie KI (1992) Eur J Pharmacol 1:107
Elsigna PH, van Waarde A, Visser GM, Vaalburg W (1994) Nucl Med Biol 21:207
Motaleb MA, Moustapha ME, Ibrahim IT (2011) JRNC 289:239–245
Law MP, Wagner S, Kopka K, Rennera C, Pike VW, Schober O, Schäfers M (2010) Nucl Med Biol 37:517
Pike VW, Law MP, Osman S, Davenport RJ, Rimordi O, Giardina D, Camici PG (2000) Pharm Acta Helv 74:191
Kopka K, Law MP, Breyholz HJ, Faust A, Höltke C, Riemann B, Schober O (2005) Curr Med Chem 12:2057
Gupta Y, Shrivastava A, Duggal D, Patel A, Agrawal S (2009) J Young Pharmacists 1:264
Moustapha ME, Motaleb MA, Ibrahim IT (2011) JRNC 287:1
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sakr, T.M., Moustapha, M.E. & Motaleb, M.A. 99mTc-nebivolol as a novel heart imaging radiopharmaceutical for myocardial infarction assessment. J Radioanal Nucl Chem 295, 1511–1516 (2013). https://doi.org/10.1007/s10967-012-2168-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-012-2168-1